Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

17.01
+0.14000.83%
Post-market: 17.010.00000.00%19:30 EDT
Volume:1.16M
Turnover:19.63M
Market Cap:5.43B
PE:35.38
High:17.11
Open:17.00
Low:16.73
Close:16.87
52wk High:19.26
52wk Low:9.49
Shares:319.00M
Float Shares:191.00M
Volume Ratio:0.66
T/O Rate:0.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4808
EPS(LYR):0.2200
ROE:613.02%
ROA:8.60%
PB:164.31
PE(LYR):77.32

Loading ...

Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results

MT Newswires Live
·
Jun 05

BUZZ-Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study

Reuters
·
Jun 05

Amneal says interim Phase 4 ELEVATE-PD data show Crexont adds about 3 hours daily “Good On” time in Parkinson’s patients

Reuters
·
Jun 05

Amneal Pharma - Phase 4 Data Show Consistent Benefits of Crexont Across All Prior Treatment Groups

THOMSON REUTERS
·
Jun 05

Amneal Announces Full Study Population Interim Phase 4 Elevate-Pd Results, Reinforcing Previously Reported Benefits of Crexont® in Parkinson's Disease

THOMSON REUTERS
·
Jun 05

Is FDA-Backed Romidepsin Launch Reshaping the Investment Case for Amneal Pharmaceuticals (AMRX)?

Simply Wall St.
·
Jun 05

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Charles River Labs (CRL) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Jun 04

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

THOMSON REUTERS
·
Jun 04

Amneal Pharma - Romidepsin Injection Solution Granted 180 Days of Market Exclusivity Under Cgt

THOMSON REUTERS
·
Jun 04

Amneal Pharmaceuticals CEO Chirag Patel to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 01

Scienture names Narasimhan Mani interim CFO after Eric Sherb resigns

Reuters
·
May 30

Amneal Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 20

Amneal Pharmaceuticals price target raised to $16 from $15 at Barclays

TIPRANKS
·
May 20

Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Radnet (RDNT) and Relay Therapeutics (RLAY)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Amneal director Deborah M. Autor disposes 34,819 shares worth $450,537.86

Reuters
·
May 13

Amneal Q1 net income more than doubles to $78 million; net revenue rises 3.9% to $722.52 million

Reuters
·
May 08

Amneal Pharmaceuticals held annual shareholder meeting, director nominees elected

Reuters
·
May 08

Amneal Pharmaceuticals Q1 Adj. EPS $0.27 Beats $0.23 Estimate, Sales $722.519M Miss $757.228M Estimate

Benzinga Earnings
·
May 08

Amneal Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 08